Dr. Brigitte Robertson, MD - CMO, Adial Pharmaceuticals - Combating Alcohol Use Disorder

Send us a text

Dr. Brigitte Robertson, MD ( https://www.adial.com/team/brigette-roberston-md/ ) is Chief Medical Officer of Adial Pharmaceuticals, a clinical-stage biopharma company focused on developing therapies for the treatment of addiction and related diseases, specifically Alcohol Use Disorder (AUD). In the U.S. alone, an estimated 35 million people suffer from AUD, resulting in significant health, social and financial costs. Current treatment options present significant barriers to patient adoption including abstinence and side effects which can lead to social stigmatization.

Dr. Robertson has nearly 20 years of academic, clinical, and pharmaceutical industry experience. She has managed global development portfolios across multiple CNS indications, mechanisms, and in biotech, small, and large pharma. Her experience spans all phases of development, from the bench to bedside, and she has actively engaged throughout her career in advancing biomarkers to improve translation and trial outcomes (leveraging precision approaches, omics, wearables and AI). She is a scientific advisor to biotech companies, has served on industry and academic consortia and authored numerous articles published in leading peer-reviewed journals.

Dr. Robertson’s industry career started at GlaxoSmithKline as a physician scientist in translational medicine for the Center for Excellence in Drug Discovery. She subsequently held senior roles in clinical development at Sepracor/Sunovion, Neurovance, Euthymics, and Shire/Takeda, where she served as VP and the Therapeutic Area Head of Neuroscience. In this last role, she led global clinical development and helped drive the disease area strategy for a large portfolio of early and late-stage assets in neurological, psychiatric, and neurodegenerative disorders, resulting in successful approvals across several indications.

Dr. Robertson then served as the Chief Medical Officer of Yumanity Therapeutics, and led development of novel small molecule treatments for neurodegenerative diseases. She comes to Adial from Delix Therapeutics, where she most recently served as CMO, setting the strategy and leading clinical development for their portfolio of psychedelic-related analogs targeting the treatment of neurodegenerative disorders, and psychiatric illness including Depression, Anxiety/PTSD, and Substance use.

Dr. Robertson completed residency training at the University of Colorado Health Sciences Center, followed by a fellowship in child and adolescent psychiatry and a second post-doctoral research fellowship, sponsored by the NIH in neuroimaging and psychopharmacology at the University of California in San Diego (UCSD). In addition, she has held faculty positions at CCP Children’s hospital in San Diego, USCD, and Duke University.

#BrigitteRobertson #AdialPharmaceuticals #Addiction #AlcoholUseDisorder #Ondansetron #DrugRepurposing #5HT3Receptor #SingleNucleotidePolymorphisms  #ProgressPotentialAndPossibilities #IraPastor #STEM #Innovation #Technology #Science #Research #Podcast #Podcaster

Support the show